Albireo Pharma (NASDAQ:ALBO) is scheduled to be issuing its quarterly earnings data before the market opens on Thursday, August 8th. Analysts expect the company to announce earnings of ($1.44) per share for the quarter.
Albireo Pharma (NASDAQ:ALBO) last announced its quarterly earnings data on Thursday, May 9th. The biopharmaceutical company reported ($1.39) EPS for the quarter, missing analysts’ consensus estimates of ($1.37) by ($0.02). Albireo Pharma had a negative net margin of 2,900.81% and a negative return on equity of 47.03%. The company had revenue of $0.57 million for the quarter, compared to analyst estimates of $1.20 million. On average, analysts expect Albireo Pharma to post $-6 EPS for the current fiscal year and $-5 EPS for the next fiscal year.
NASDAQ ALBO opened at $26.01 on Friday. Albireo Pharma has a 1-year low of $19.10 and a 1-year high of $38.69. The firm has a market capitalization of $337.46 million, a P/E ratio of -6.47 and a beta of 1.56. The stock has a fifty day moving average of $30.19.
Several equities analysts have commented on the stock. ValuEngine raised shares of Albireo Pharma from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, July 2nd. HC Wainwright restated a “buy” rating and set a $62.00 price target on shares of Albireo Pharma in a report on Wednesday, July 10th. BidaskClub cut shares of Albireo Pharma from a “hold” rating to a “sell” rating in a research note on Wednesday, July 24th. Zacks Investment Research raised shares of Albireo Pharma from a “sell” rating to a “hold” rating in a research report on Tuesday, May 14th. Finally, Wedbush set a $69.00 price objective on shares of Albireo Pharma and gave the stock a “buy” rating in a report on Thursday, July 11th. One analyst has rated the stock with a sell rating, one has issued a hold rating, five have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $60.33.
About Albireo Pharma
Albireo Pharma, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI) disorders in the United States. Its lead product candidate is A4250, an orally administered ileal sodium dependent bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating progressive familial intrahepatic cholestasis and phase II clinical trial for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases.
See Also: QQQ ETF
Receive News & Ratings for Albireo Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albireo Pharma and related companies with MarketBeat.com's FREE daily email newsletter.